A single polypeptide of the HIV-1 reverse transcriptase that reconstituted Mg 2؉ -dependent RNase H activity has been made. Using molecular modeling, the construct was designed to encode the p51 subunit joined by a linker to the thumb (T), connection (C), and RNase H (R) domains of p66. This p51-G-TCR construct was purified from the soluble fraction of an Escherichia coli strain, MIC2067(DE3), lacking endogenous RNase HI and HII. The p51-G-TCR RNase H construct displayed Mg 2؉ -dependent activity using a fluorescent nonspecific assay and showed the same cleavage pattern as HIV-1 reverse transcriptase (RT) on substrates that mimic the tRNA removal required for second-strand transfer reactions. The mutant E706Q (E478Q in RT) was purified under similar conditions and was not active. The RNase H of the p51-G-TCR RNase H construct and wild type HIV-1 RT had similar K m s for an RNA-DNA hybrid substrate and showed similar inhibition kinetics to two known inhibitors of the HIV-1 RT RNase H.
The HIV reverse transcriptase (RT) has been a major target for antiviral drug development. The enzyme contains three activities: RNA-and DNA-dependent DNA polymerase activities and RNase H activity. Currently, all clinically approved RT inhibitors target the polymerase function. RNase H cleaves RNA within a RNA-DNA hybrid and is essential for viral replication (7, 32, 33, 36) . RNase H inhibitors are currently being developed as antiviral agents (35) . Several classes of HIV RNase H inhibitors, which act through distinct mechanisms, have been identified, including tropolones (5) , N-hydroxyimides (16, 24) , dihydroxy benzoyl naphthyl hydrazones (DHBNH) (17) , diketo acids (4, 38, 45) , and dimeric lactones (11) .
The HIV-1 RT is heterodimer consisting of a p66 subunit and a p51 subunit (2, 26) . The RNase H (R) domain is unique to the C terminus of p66. The shape of the asymmetric heterodimer has been related to a right hand with subdomains fingers (F), palm (P), thumb (T), and connection (C), in addition to RNase H. RNase H cleavages have been further classified as polymerase dependent or polymerase independent, where polymerase-dependent cleavages are defined as those that are coupled approximately 18 nucleotides from the positioning of the 3Ј OH in the polymerase active site (14, 46) . Two structures of RNase H molecules complexed with RNA-DNA have been obtained. The first is with the Bacillus halodurans RNase H (31); the second is with HIV RT in complex with a noncleavable 3Ј polypurine tract (PPT) hybrid (37) . Through structural and biochemical studies, limited regions of RT have been identified to be in close contact with nucleic acid substrates. Within RT, both DNA-DNA (19) and RNA-DNA (37) substrates display a bend of approximately 40°b etween the polymerase active site and the p66 thumb. With respect to RNase H, two specific regions are of interest. The first is the minor groove binding track (MGBT) within the p66 thumb domain (residues 258 to 266 of helix H) (3, 27) . The second is the RNase H primer grip domain, which contacts the DNA primer strand (37) . Biochemical studies have suggested the possibility of alternative binding orientations of the RNA-DNA hybrid with RT (13) . Cross-linking studies on an HIV-1 RNase H domain also agree with this hypothesis (15) . Recently, single-molecule fluorescence resonance energy transfer was used to examine the interactions between RT and nucleic acid substrates in real time. These studies show that the RNA-DNA hybrid can bind in two orientations (28) and that the orientation of the RT depends on the composition of the substrate (RNA-DNA versus DNA-DNA) (1) .
Previous attempts to express the HIV-1 RNase H as a catalytically active domain have been possible only in the presence of Mn 2ϩ , and many of these attempts required an alternative substrate binding domain (16, 21, 39, 40, 42, 47) . The role of metal binding in the RNase H domain of HIV has been a controversial area. Reports of one and two metal binding sites have been described both biochemically and structurally (10, 12, 29, 34) . The presence of Mn 2ϩ has been shown to induce conformational changes within the RNase H as well as activate known RNase H catalytic site mutations (E478Q) (8, 15, 29, 34) . In addition, many of the candidate drugs identified have the potential to bind to metals (5, 24, 38) . It has been postulated that the Mn 2ϩ -dependent activity might not reflect the catalytic activity of the native protein (9) . Mg 2ϩ -dependent RNase H activity could be reconstituted using specific combinations of RT subdomains, with optimal activity obtained with p51 plus a TCR construct initiating at Q222 (40) . In the study described in this report, this combination of p51 plus TCR has been generated within a single polypeptide (p51-G-TCR). Expression and purification of the p51-G-TCR RNase H construct indicated that Mg 2ϩ -dependent RNase H activity was maintained. This HIV-1 RNase H construct has the potential to greatly assist in mechanistic, structural, as well as drug discovery studies aimed at targeting the RNase H function of HIV-1 RT.
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Construction of E706Q P51-G-TCR mutant. E706 in construct G corresponds to E478 in HIV-1 RT. E706Q P51-G-TCR was made as described by Ko and Ma (25) . Construct G was amplified using pET p51-G-TCR as template with two pairs of DNA primers. Pair 1 was the T7 promoter (5Ј-TAATACGACTCACT ATAGGG) and a reverse mutagenic primer (5Ј-AACTCTTCTCTGAGTCTTC TGATTTGTTGTGTC). Pair 2 was forward mutagenic primer E706Q fwd (5Ј-AACTCTTCTCAGTTACAAGCAATTTATCTAGC) and the T7 terminator (5Ј-GCTAGTTATTGCTCAGCGG). Mutagenic primers contain the sequence for an E-to-Q change and a restriction site for EarI.
The amplification reaction mixture contained 1.25 U of GoTaq Flexi DNA polymerase (Promega), 200 M deoxynucleoside triphosphates, 1 M primers, and 100 ng of p51-G-TCR in 50 l of 1ϫ reaction GoTaq Flexi buffer (Promega). The amplified DNA fragments were purified using a Wizard PCR Preps kit (Promega), digested with EarI, and purified with the same kit. The fragments were then ligated with T4 ligase, and the 2,513-bp ligation product was purified by electrophoresis on 1% agarose and then ligated to pGEM-T Easy and used to transform E. coli JM109 cells. Colonies containing plasmids with the E706Q mutation were identified by DNA sequencing. Purified plasmid was digested with NdeI and BamHI, and the released 2,378-bp product was purified by electrophoresis on a 1% agarose gel and ligated to the 6HisT-pET11 vector, yielding E706Q P51-G-TCR.
Molecular modeling. The molecular modeling was performed using the O program (20) . The surface potential was determined using the program Graphical Representation and Analysis of Surface Properties (GRASP) (30) .
Complementation assay. Plasmids were transformed into competent MIC2067(DE3) cells and plated onto LB agar with chloramphenicol, kanamycin, and carbenicillin (30 g/ml, 50 g/ml, and 100 g/ml, respectively). MIC2067(DE3) cells were grown at either the permissive (30°C) or the nonpermissive (42°C) temperature. BL21(DE3) cells were cultured overnight in LB broth at 37°C, and BL21 cells containing the pHTP51ETCR plasmid were cultured overnight in LB-carbenicillin (100 g/ml) broth at 37°C.
Protein expression and purification. Procedures for expression and purification of recombinant proteins are described in the supplemental material.
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P-labeled RNA-DNA hybrid production. Preparation and labeling of the hybrid 17-mer DNA-RNA or DNA-DNA substrate mimic were performed as previously described (41) .
Dynamic light scattering. Dynamic light scattering measurements were performed at 20°C using 100 l of sample in Uvettes disposable cuvettes (Eppendorf) with a Zetasizer Nano-S apparatus (Malvern). The samples were diluted with 20 mM HEPES, pH 7.4, 1.5 mM dithiothreitol, 400 mM KCl, 0.1% NP-40, 20% glycerol. The viscosity value was 1.7500 cP, corresponding to a 20% glycerol solution at 20°C. These analyses were performed at the Institute Pasteur of Montevideo, Montevideo, Uruguay.
RNase H fluorescence assay. The RNase H fluorescence assay was carried out essentially as described previously (35) . The reaction was carried out at 37°C in a 96-well plate in a final volume of 100 l. The reaction mixture contained 0.25 M DNA-RNA substrate, 50 mM Tris, pH 8.0, 60 KCl mM, and 5 mM MgCl 2 . RNase H activity was detected by the increase of fluorescence at 525 nm due to substrate hydrolysis using an excitation wavelength of 490 nm. Fluorescence was measured using a Fluoroskan II apparatus, and data analysis was carried out using the program Spectrosoft (MTX Lab Systems).
RNase H inhibition assays. To determine the susceptibility of RNase H construct G to known HIV-1 RNase H inhibitors, we tested the tropolone derivative ␤-thujaplicinol over a concentration range from 6.9 ϫ 10 Ϫ10 M to 6.9 ϫ 10 Ϫ4 M and an N-hydroxyimide, ARK-2456, over a concentration range of from 7.05 ϫ 10 Ϫ10 M to 7.05 10 Ϫ4 M. Both compounds were dissolved in dimethyl sulfoxide (DMSO) and added to the RNase H reaction mixtures. The DMSO concentration in the assay was 5%. The fluorescence assay was used under the conditions described above. Fifty percent inhibitory concentrations (IC 50 s) were determined by nonlinear regression using GraphPad Prism software, version 5. ␤-Thujaplicinol was obtained from Molecular Diversity Preservation International (Basel, Switzerland), and ARK-2456 was obtained from the Florida Center for Heterocyclic Compounds. tRNA removal assay. The activity of the collected fractions was determined in a reaction mixture (10 l) containing 50 mM Tris-HCl, 50 mM KCl, 8 mM MgCl 2 or MnCl 2 , 1 pmol of substrate, and 1 to 2 pmol of the enzyme. After 30 min at 37°C, 10 l of 2ϫ formamide stop buffer was added and the products of the reaction were separated by electrophoresis on a 20% acrylamide-7 M urea gel.
RESULTS
An important tool for studying the HIV RT RNase H as well as for drug screening is an RNase H construct that maintains the specificity and biochemical properties of the wild-type (WT) enzyme. Reconstitution studies using reverse transcriptase subdomains had indicated that Mg 2ϩ -dependent RNase H activity could be robustly restored in the presence of two components: p51 plus a p66 C-terminal construct encoding TCR (Q222) (40) . Molecular modeling was utilized to design constructs which incorporated this combination of RT subdomains within a single polypeptide.
Design criteria. Figure 1 outlines the constructs that were developed and that joined the p51 polypeptide with the p66 TCR domains through a linker region. Deletion and biochemical studies of p51 had indicated that the C terminus influences RNase H cleavage and RT properties (6) . The C terminus of p51 terminates on the back face of the protein, on the opposite side of the polymerase and RNase H active sites. This greatly facilitated the modeling of the linker, as it avoided generating a linker that would interfere with the pathway of substrate binding. The linker region between the p66 thumb and p51 connection spans a direct linear distance of 62 Å. The linker was designed to maintain a solvent-accessible hydrophilic face to improve solubility. Linker G consists of 33 amino acids derived from residues 85 to 102 of HIV-1 p66, a flexible region. Codons for the linker were optimized for expression in E. coli, and the construct contains an N-terminal His 6 tag, followed by the thrombin cleavage site. Linker E is 2 amino acids shorter than linker G.
Molecular modeling and surface potential of p51-linker-TCR constructs. Figure 2B compares the molecular model of the p51-E-TCR constructs with that of the WT HIV-1 RT heterodimer ( Fig. 2A) . In the p51-E-TCR model, the linker is flexible and the side chains of the amino acids have no interaction with any of the residues of the p51-TCR backbone.
Of key importance was whether the RNase H constructs maintained surface charges that mimicked the WT protein. To analyze this, the surface potential of the p51-E-TCR (Fig. 2D ) construct was compared with that of the WT HIV-1 RT heterodimer (Fig. 2C) . The surface potential of the p51-E-TCR construct mimics rather well the homologous region of the HIV heterodimer. Of interest is the deep, highly positive region (blue) prior to the RNase H, indicating that the primer grip and minor groove binding track of the p66 thumb are likely to be maintained. Changes in the individual construct compared with the WT RT are due to the energy minimizations performed on each molecular model. In addition, docking experiments with a 23-mer-22-mer RNA-DNA hybrid heterodimer is shown on the top, where subdomains are labeled F (fingers), P (palm) T (thumb), C (connection), and R (RNase H). The boundaries of the subdomains are marked above the sequence and are based on HXB2. Domains of p66 and p51 are color coded, where p51 FP domains are gray, p66 FP domains are white, the p66 thumb domain is blue, the p51 thumb domain is turquoise, the p66 connection is yellow, the p51 connection is orange, and RNase H is green. The general scheme for the p51-linker-TCR construct is outlined at the bottom using the color scheme defined for p66/p51. The construct encodes an N-terminal His (Fig. 1 ) to complement MIC2067 growth at 30°C and 42°C was tested (Fig. 3) . At 30°C (Fig. 3B) , growth was detected in all strains, as predicted. At 42°C (Fig. 3C) , the growth of BL21(DE3) cells was normal; however, MIC2067(DE3) was ts for growth. With introduction of HIV p51, lacking the RNase H domain, the MIC2067(DE3) remained ts. Considerable growth was observed when the p51-E-TCR construct was introduced into the MIC2067(DE3) cells. This indicates that the construct provides sufficient RNase H activity to complement E. coli growth at 42°C. These results are extremely supportive of the suggestion that molecularly designed HIV-1 RNase H single polypeptide constructs provide a soluble, functional RNase H. Protein expression. Plasmid encoding p51-E-TCR was assembled through a generalized scheme. Briefly, the linker regions were assembled using overlapping PCR and inserted into the p51 construct through the KpnI-BamHI sites (Fig. 1A ). The TCR region was then inserted into linker-positive isolates through the PvuII-BamHI sites, generating p51-E-TCR. p51-G-TCR was obtained by adding 2 amino acids in the linker by site-directed mutagenesis (Fig. 1B) . Plasmids were introduced into E. coli MIC6067(DE3) and induced for expression by isopropyl-␤-D-thiogalactopyranoside. Initially, purification of the constructs indicated that p51-G-TCR was more stable than p51-E-TCR (see Fig. S1 in the supplemental material); therefore, construct p51-G-TCR was used in the following studies.
Whole-cell extracts of individual colonies from the control pET15B plasmid, p51-G-TCR, and p51-G-TCR E706Q were analyzed on SDS-polyacrylamide gels by Coomassie blue staining and Western blotting using a His 6 tag detection reagent.
Comparison of the control pET15B extract with the p51-G-TCR and p51-G-TCR E706Q extracts showed a protein product which corresponded with the predicted full-length 93-kDa protein. This observation was confirmed by Western blotting (see Fig. S2 in the supplemental material) .
Protein purification. MIC2067(DE3) cells harboring a plasmid containing the p51-G-TCR construct were autoinduced (43) to increase production of soluble proteins. Furthermore, to make sure that the RNase H activity is due to the expression of the p51-G-TCR protein, we replaced the amino acid residue E706 in p51-G-TCR that corresponds to E478 in HIV-1 RT with glutamine. E478Q HIV-1 RT lacks RNase H activity in Mg 2ϩ (8) . p51-G-TCR and p51-G-TCR E478Q were purified from the soluble fraction and chromatographed on nickel nitrilotriacetic acid (Ni 2ϩ -NTA) resin. The purity of the proteins was greater than 90%, as judged by SDS-PAGE (see Fig. S3 in the supplemental material). Analysis of the p51-G-TCR protein solutions at 0.25 and 2.0 mg/ml by dynamic light scattering indicated that more than 98% of the protein is a monomer (results not shown).
Characterization of magnesium-dependent RNase H activity of p51-G-TCR. The RNase H activity of the RNase H constructs was determined in the presence of Mg 2ϩ by the fluorescence assay as described in Materials and Methods. As shown in Fig. 4 , the RNase H activity of p51-G-TCR was similar to that of HIV-1 RT, whereas E706Q was inactive, as expected, ruling out potential contamination with E. coli RNase H. To compare the kinetic properties of the p51-G-TCR protein and HIV-1 RT, we determined the K m using the fluorescence assay. Under our conditions, the K m s for the RNase H activity of p51-G-TCR and HIV-1 RT were 0.036 Ϯ 0.020 and 0.025 Ϯ 0.012 M, respectively, suggesting that the structure of the substrate binding site was maintained in p51-G-TCR. tRNA removal assay. Fractions eluting from the Ni 2ϩ -NTA column were assayed for Mg 2ϩ -and Mn 2ϩ -dependent RNase H activity using a specific cleavage reaction. Figure 5B compares the activities of E. coli RNase H, HIV-1 RT, and p51-G-TCR on the RNA-DNA substrate shown in Fig. 5A . The specific cleavage patterns of the substrate that were detected for HIV-RT and p51-G-TCR in Mg 2ϩ were distinct from the cleavage pattern of E. coli RNase H. The cleavage patterns for the HIV-1 RT and p51-G-TCR construct correspond to the release of the 11-mer RNA, corresponding with the authentic cleavage identified in vivo. Of considerable interest is the fact that the relative activity of the isolated HIV-1 RNase H (p51-G-TCR) was comparable to that of the full-length HIV RT. Construct G maintained Mn 2ϩ -dependent activity and resulted in processive cleavage of the substrate into smaller products (Fig. 5C) .
Effects of ␤-thujaplicinol and ARK-2452 on p51-G-TCR RNase H activity. ␤-Thujaplicinol and ARK-2452 are known inhibitors of HIV-1 RT RNase H (16, 18) . In order to assess the correct folding of the inhibitor binding sites in p51-G-TCR, we determined the IC 50 using wild-type HIV-1 RT as a control. The results are shown in Fig. 6 and summarized in Table 1 . ␤-Thujaplicinol (Fig. 6A and B) and ARK-2452 (6C and D) inhibited both HIV-1 RT and p51-G-TCR with IC 50 s in the same order of magnitude. Taken together, these results indicate that the essential catalytic properties of the RNase H domain were maintained in p51-G-TCR. (47) . The p51-G-TCR Mg 2ϩ -dependent RNase H construct differs from the prior TCCR construct by incorporating the p66 thumb and MGBT as well as the p51 finger-palm domain. Complementation studies (40) indicated that restoration of Mg 2ϩ activity required the presence of subdomains of p51 and the T subdomain of p66. Accordingly, our results with the p51-G-TCR construct confirm these observations, indicating that the RNase H active site is stabilized by these RT subdomains, providing the conformation needed for catalysis with Mg Nonnucleoside RT inhibitors (NNRTIs) bind to the base of the thumb and have been shown to enhance RNase H cleavage and increase the angle between the polymerase active site-NNRTI binding site and the RNase H active site by 10°. In the RT-PPT crystal structure, it was noted that minor alterations in the substrate trajectory of 2 Å could reposition an RNA-DNA hybrid out of the RNase H catalytic core. Thus, the overall positioning of the substrate within the RNase H active site appears to be critical for the maintenance of Mg 2ϩ -dependent RNase H activity. The mechanism by which the substrate binding regulates the reverse transcriptase activity remains unclear; apparently, the activities of RT, DNA synthesis, and RNA hydrolysis are determined by its binding orientation on substrates. It has been reported that RT adopted opposite binding orientations on duplexes containing DNA or RNA primers (1, 13) . The RNase H construct that has Mg 2ϩ -dependent activity in the absence of polymerization will be useful to determine the substrate orientation during tRNA removal.
The RNase H activity within the viral RT is being developed as a target for drug development. Initial screens have utilized the full-length RT. Due to the complexity of the enzymes, inhibitors can affect RNase H activity directly through the RNase H active site or indirectly through positioning of the RNA-DNA template. The use of truncated RT constructs lacking the polymerase active site and NNRTI binding sites could assist in localizing the effects of lead compounds in secondary screens. The crystal structures of the complexes of HIV-1 RT with ␤-thujaplicinol (18), a naphthyridinone derivative (44) , and pyrimidol carboxylic acids (23) have been solved. The p51-G-TCR construct could be used for similar structural analysis of RNase H inhibitors in the absence of a polymerase active site. In conclusion, the p51-G-TCR construct should be valuable for drug screening and a useful model for basic studies on RNA-DNA recognition and polymerase-independent RNase H cleavage.
